Clinical Trial

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

Study acronym: REPERFUSE
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-28.
Status change: Not Yet Recruiting → Recruiting 2025-04-01
Trial Details
NCT Number NCT06234592
Lead Sponsor King's College Hospital NHS Trust
Collaborators: European Society of Intensive Care Medicine, Royal Centre for Defence Medicine
Conditions Septic Shock, Acute Kidney Injury
Enrollment 45 participants
Start Date 2024-01-05
Primary Completion 2026-01 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-04-04